000			03822nam a22003975i 4500
999			_c393323 _d393323
001			393323
003			ES-MaUEC
005			20240217102557.0
006			a||||fo|||| 00| 0
007			cr nn 008mamaa
008			100301s2004 xxu| fo |||| 0|eng d
020			_a9781592596584
024	7		_a10.1385/1592596584 _2doi
040			_aES-MaUEC _bspa _cES-MaUEC _dES-MaUEC
050		4	_aRM340 _b2004 EB
245	0	0	_aAnticoagulants, Antiplatelets, and Thrombolytics _cedited by Shaker A. Mousa.
250			_a1st edition 2004
264		1	_aTotowa, NJ _bHumana Press _c2004
300			_a1 recurso en línea (X, 310 páginas)
336			_atexto _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
347			_aarchivo de texto _bPDF
490	0		_aMethods in Molecular Medicine _x1940-6037 _v93
505	0		_aHighlights of Latest Advances in Antithrombotics -- Antiplatelet, Anticoagulant, and Thrombolytic Drug Interactions -- Evaluation of Platelet Antagonists in In Vitro Flow Models of Thrombosis -- Heparin and Low Molecular Weight Heparin in Thrombosis, Cancer, and Inflammatory Diseases -- Are Low Molecular Weight Heparins the Same? -- Antithrombotic Drugs for the Treatment of Heparin-Induced Thrombocytopenia -- Laboratory Methods for Heparin-Induced Thrombocytopenia -- Factor Xa Inhibitors -- Tissue Factor/VIIa in Thrombosis and Cancer -- Tissue Factor Pathway Inhibitor in Thrombosis and Beyond -- Cell Adhesion Molecules -- Development and Applications of Animal Models of Thrombosis -- A Survey of Venous Thrombosis Models -- Arixtra® (Fondaparinux Sodium) -- Oral Thrombin Inhibitor Ximelagatran -- Pharmacogenomics and Coagulation Disorders -- Guidelines for Diagnosis and Treatment of Deep Venous Thrombosis and Pulmonary Embolism.
520			_aDuring the past decade, remarkable progress has been made in the development of new drugs to treat thrombotic and cardiovascular diseases, the number one cause of mortality worldwide. In Anticoagulants, Antiplatelets, and Thrombolytics, leading experts with established records of discovery and invention highlight the latest developments in antithrombotics and provide experimental methods for the discovery of new and improved anticoagulants. Among the cutting-edge developments reviewed are the novel usage of low molecular weight heparins, such antithrombin agents as hirudin, and such antiplatelet drugs as the GPIIb/IIIa inhibitors and ADP-receptor antagonists. Additional innovations discussed include aspirin and clopidogrel, the expanded use of polytherapeutic approaches, antiproteases (factors IIa, Xa, and VIIa), tissue-factor targeting, platelet-receptor targeting, and antithrombin III modulation. The authors also define the clinically relevant in vitro and in vivo models of thrombosis and hemostasis that led to these advances and that will surely aid in the discovery of the next generation of antithrombotics. Up-to-date and forward-looking, Anticoagulants, Antiplatelets, and Thrombolytics illuminates the latest developments in the field of thrombosis and provides both basic and clinical investigators a broad array of successful experimental methods for the discovery and development of novel drugs to treat thrombotic and cardiovascular diseases.
988			_aSpringer_Protocols_2004
650		7	_2embne _9144124 _aAnticoagulantes
776	0	8	_iPrinted edition: _z9781617373466
776	0	8	_iPrinted edition: _z9781588290830
776	0	8	_iPrinted edition: _z9781489939791
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1385/1592596584 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
942			_2lcc _cLE
998			_b12/2023 _dz _ean _zSI